This vitamin C serum leaves skin 'glowing' — and it's only $20 on Amazon Canada
Vitamin C Serum Plus With Hyaluronic Acid Serum
More than 5,000 shoppers purchased this "Amazon's Choice" serum in the past month.
Why is it a good deal? 💰
Finding a quality vitamin C serum that actually yields results is *chef's kiss.* But landing one that's affordable, too? Perfection. Other serums can cost $45 or more for the same amount of product, so this is an absolute steal.
Why do I need this? 🧐
The Eva Naturals Vitamin C Serum is made primarily of vitamins C, E and B3, along with retinol, salicylic and hyaluronic acids. These ingredients are known to aid in preserving skin's suppleness and in preventing visible signs of aging. They can also help clear up breakouts and acne scars and improve overall skin tone and texture.
What reviewers say 💬
With more than 52,000 Amazon reviews, it's fair to say this serum is a clear winner.
Pros 👍
"This by far has been my favourite vitamin C serum," declared one. "I've used high-end and drugstore brands and this leaves my skin glowing every time, especially for the price point. It has hyaluronic acid, so it hydrates the skin and just leaves my skin feeling supple and soft. I've been using it for years and don't plan to stop!"
It gives a glowing complexion, as another serum convert confirmed: "This stuff is so amazing; after just a couple of weeks of use, I saw such a difference (and I'm 60 years old!). Honestly, I keep touching my face — it's so smooth and soft and moisturized. But don't take my word for it: My boyfriend (hey, 60 is the new 40!) regularly tells me how much he 'loves' my skin, that my skin is so great."
"Both my husband and I are using this serum," a pleased Amazon shopper wrote. "It is moisturizing and my husband says it's helping with darker pigmentation on his skin. I had a small dry red area and it's now gone. A little goes a long way, too. My skin tends to be very sensitive and I have no reaction to this. Very happy."
Vitamin C Serum Plus With Hyaluronic Acid Serum
This popular vitamin C serum has more than 52,000 reviews on Amazon.
Cons 👎
As with any vitamin C product, be sure to test it on your skin before using it. One customer said, "I burned my face with this multiple times before finally getting the hang of it. I resisted the urge to quit and spent a couple of months figuring out what makes my sensitive combination skin happy. ... This product has made a notable difference in the texture of my skin, it has shrunk my pores and faded my acne scars."
Another shopper thought the dispenser could use improvement: "I was looking for a new first step in my routine and this serum is a great one! It's all in one. It has kept my skin looking great and smooth! I love it! Wish it came in a pump though! Absorbs awesomely too. I then add my moisturizer with SPF, then sunscreen to finish up my daily skin routine.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
AstraZeneca to invest $50 bln in US as pharma tariffs loom
STORY: AstraZeneca plans to invest $50 billion in the U.S. by 2030. The Anglo-Swedish drugs giant said Monday (July 21) that the money will fund a new factory in Virginia, and expand other facilities in states including California. It's the latest big player to make a move as Donald Trump's threat of tariffs hangs over the pharmaceutical industry. He's also pushing companies to make more of their products in the U.S. And he wants American drug costs to fall to levels seen elsewhere in the world. Announcing the investment plans, AstraZeneca chief Pascal Soriot said prices did need to equalize. He said drug charges elsewhere would need to rise, so that other countries contribute more to research and development costs. Exactly what Trump plans on tariffs remains unclear. ::July 15, 2025 "Pharmaceuticals will be tariffed, probably at the end of the month." He's repeatedly threatened to impose duties on the sector, but has also said that firms will be allowed up to 18 months to 'get their act together'. In a statement issued by the company, Commerce Secretary Howard Lutnick said Trump's tariffs will end America's long reliance on imported medicines. AstraZeneca's investment follows similar moves by European rivals like Roche, Sanofi and Novartis. U.S. players including Eli Lilly have also stepped up domestic spending. AstraZeneca says its plan will create tens of thousands of new jobs, without giving a specific number. Sign in to access your portfolio
New York Times
20 minutes ago
- New York Times
L.A. Times Owner Says He Will Take Newspaper Public in Next Year
The owner of the Los Angeles Times, Patrick Soon-Shiong, said on Monday that he would take the newspaper public in the next year. Dr. Soon-Shiong, a former surgeon who built his fortune by developing cancer drugs, bought the Los Angeles Times in 2018 for $500 million from Tronc, a media company that was, at the time, listed on the New York Stock Exchange. Since taking over the newspaper, Dr. Soon-Shiong has struggled to make it profitable, and a history of deep losses would cloud its appeal to investors. AdWeek reported that the L.A. Times lost $50 million in 2024 as paid subscriptions fell to just over 300,000. The newspaper laid off more than 20 percent of its newsroom staff last year. A public offering would happen 'over the next year,' Dr. Soon-Shiong said on 'The Daily Show' in a taped interview with the host, Jon Stewart. He did not share any details or address whether this would dilute his control over the newspaper. The 2018 purchase was carried out by Nant Capital, his private investment arm. That acquisition placed the newspaper under local ownership for the first time in nearly two decades, but his public comments in the past year and his decisions about editorial direction have stirred unrest in the newsroom. Last year, the head of the editorial board resigned after Dr. Soon-Shiong prevented the newspaper from endorsing Vice President Kamala Harris for president. Dr. Soon-Shiong said on The Daily Show on Monday that taking the company public would 'democratize' it and would allow the public to 'take ownership,' though he did not detail how that would work.
Yahoo
38 minutes ago
- Yahoo
These two cancer drugs may help lower your risk of Alzheimer's disease, study shows
Scientists have identified two cancer drugs that may also lower the risk of Alzheimer's disease as they search for some way to lower its impact on an aging population. In a study published on Monday in the medical journal Cell, researchers from the University of California, San Francisco, combed through more than 1,300 candidate drugs — from antipsychotics to antibiotics — for anything that could help alleviate the incurable condition. Only 90 of those drugs targeted the brain cell genes thought to influence Alzheimer's, and of those only five showed evidence of actually reducing the risk of Alzheimer's in human patients. The scientists then chose letrozole, designed to fight breast cancer, and irinotecan, intended for treating colon and lung cancer, to test on mice. 'We didn't expect cancer drugs to come up," study co-author Marina Sirota told NBC News. In fact, the two drugs used in combination did appear to improve memory and brain function in aging mice who had begun to show signs of dementia. The effects still need to be proven in human studies (PA Wire) That result still needs to be tested in humans, and the drugs may prove less effective in humans. Still, the finding is significant because pharmaceutical companies have so far struggled to develop purpose-built drugs for the disease. "Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than ten years," said study co-author Dr. Yadong Huang. "For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower. "We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline," he added. Over seven million Americans live with Alzheimer's disease, according to the Alzheimer's Association, including 1 in 9 people aged over 65. The number is only likely to grow as the average age of the U.S. population continues to climb, with care costs for people with dementia projected to grow from $384 billion in 2025 to nearly $1 trillion by 2050.
